BROOKLYN IMMUNOTHERAPEUTICS (BTX)
US1140821000 - Common Stock
| MRQ (2022-6-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 19.41M | 16.98M | N/A | N/A | N/A | |||
| Cash Equivalents | N/A | N/A | 777.00K | 3.21M | 2.54M | |||
| Receivables | 694.00K | 684.00K | 116.00K | 1.20M | 1.14M | |||
| Other Current Assets | 1.82M | 1.10M | 831.00K | 1.67M | 3.11M | |||
| Total Current Assets | 21.93M | 18.77M | 1.72M | 6.07M | 6.79M | |||
| Non-Current Assets | ||||||||
| PPE Net | 2.46M | 4.24M | 538.00K | 4.92M | 4.67M | |||
| Investments And Advances | 477.00K | 488.00K | N/A | N/A | N/A | |||
| Goodwill | 2.04M | 2.04M | 0.00 | 696.00K | 667.00K | |||
| Intangibles | 0.00 | 5.99M | 1.36M | 1.92M | 2.02M | |||
| Other Non-Current Assets | N/A | N/A | 122.00K | 521.00K | 727.00K | |||
| Total Non-Current Assets | 4.98M | 12.76M | 2.02M | 8.05M | 8.08M | |||
| TOTAL ASSETS | 26.90M | 31.52M | 3.75M | 14.13M | 14.86M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 1.52M | 2.76M | 1.04M | |||
| Accrued Expenses | 4.21M | 1.68M | 344.00K | 1.62M | 1.10M | |||
| Accounts Payable | 1.48M | 1.75M | 270.00K | 835.00K | 271.00K | |||
| Other Current Liabilities | 1.43M | 247.00K | 224.00K | 882.00K | 1.60M | |||
| Total Current Liabilities | 7.12M | 3.68M | 2.36M | 6.09M | 4.02M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 532.00K | 20.00K | 2.77M | |||
| Other Non-Current Liabilities | 5.00M | 2.35M | 2.00K | 2.92M | 1.15M | |||
| Total Non-Current Liabilities | 5.00M | 2.35M | 534.00K | 2.94M | 3.92M | |||
| TOTAL LIABILITIES | 12.12M | 6.02M | 2.89M | 9.03M | 7.95M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -153.48M | -140.70M | -135.89M | -131.46M | -129.39M | |||
| Additional Paid In Capital | 167.97M | 165.94M | 136.93M | 136.72M | 136.55M | |||
| Common Shares | 288.00K | 261.00K | 16.00K | 15.00K | 15.00K | |||
| Treasury Stock | N/A | N/A | -456.00K | -456.00K | -456.00K | |||
| Other Shareholders' Equity | N/A | 0.00 | 245.00K | 268.00K | 200.00K | |||
| Shares Outstanding | 57.47M | 52.02M | 1.48M | 1.45M | 1.44M | |||
| Tangible Book Value per Share | 0.22 | 0.34 | -0.35 | 1.71 | 2.94 | |||
| Total Shareholders' Equity | 14.78M | 25.50M | 851.00K | 5.09M | 6.92M | |||
| TOTAL LIABILITIES AND EQUITY | 26.90M | 31.52M | 3.75M | 14.13M | 14.86M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | 0.63 | 0.00 | 0.40 | |||
| Current Ratio | 3.08 | 5.10 | 0.73 | 1.00 | 1.69 | |||
| Return On Assets (ROA) | -399.71% | -388.72% | -117.89% | -14.49% | -1.74% | |||
| Return On Equity (ROE) | -727.59% | -480.51% | -518.80% | -40.21% | -3.74% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | 3.38% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | 4.41% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | 6.52% | |||
All data in USD